Key Words. FDA summary Metastatic breast cancer Multidrug resistant Lapatinib Capecitabine
|
|
- Sara Newman
- 5 years ago
- Views:
Transcription
1 The Oncologist Regulatory Issues FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2 QIN RYAN, AMNA IBRAHIM, MARTIN H. COHEN, JOHN JOHNSON, CHIA-WEN KO, RAJESHWARI SRIDHARA, ROBERT JUSTICE,RICHARD PAZDUR Division of Drug Oncology Products, Office of Oncology Drug Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA Key Words. FDA summary Metastatic breast cancer Multidrug resistant Lapatinib Capecitabine Disclosure: The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers. LEARNING OBJECTIVES After completing this course, the reader should be able to: 1. Describe the clinical trial that led to the approval of lapatinib in combination with capecitabine for the treatment of previously treated patients with HER-2 overexpressing metastatic breast cancer. 2. Determine appropriate patients to receive lapatinib plus capecitabine treatment. 3. Assess and manage the toxicities of lapatinib plus capecitabine treatment. CME This article is available for continuing medical education credit at CME.TheOncologist.com. ABSTRACT On March 13, 2007, the U.S. Food and Drug Administration approved lapatinib (Tykerb tablets; Glaxo- SmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2 overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab. One multicenter, open-label, randomized trial was submitted. Eligible patients had stage IIIb or IV breast cancer, ErbB-2 overexpression (immunohistochemistry 3 or 2 with fluorescence in situ hybridization confirmation), measurable disease, a 0 or 1 Eastern Cooperative Oncology Group performance status score, a cardiac ejection fraction within the institutional normal range, and adequate laboratory function. Patients received either lapatinib (1,250 mg once daily on days 1 21) plus capecitabine (1,000 mg/m 2 every 12 hours on days 1 14) every 21 days or capecitabine alone (1,250 mg/m 2 every 12 hours on days 1 14) every 21 days. The primary endpoint was time to progression (TTP) determined by a blinded independent review panel. Af- Correspondence: Qin Ryan, M.D., Ph.D., Division of Oncology Drug Products, U.S. Food and Drug Administration, Silver Spring, Maryland 20993, USA. Telephone: ; Fax: ; qin.ryan@fda.hhs.gov Received January 23, 2008; accepted for publication August 6, 2008; first published online in THE ONCOLOGIST Express on October 10, AlphaMed Press /2008/$30.00/0 doi: /theoncologist The Oncologist 2008;13:
2 Ryan, Ibrahim, Cohen et al ter TTP results of a prespecified interim analysis were made available, study enrollment was discontinued (399 patients enrolled). The median TTP was 27.1 versus 18.6 weeks (hazard ratio, 0.57; p.00013) favoring the lapatinib plus capecitabine arm. Response rates were 23.7 (lapatinib plus capecitabine) versus 13.9 (capecitabine alone). Survival data were not mature. Although the toxicities observed in the lapatinib and capecitabine combination arm were generally similar to those in the capecitabine alone arm, a higher incidence of diarrhea and rash was noted with the combination. 3 or 4 adverse reactions that occurred with a frequency of >5 in patients on the combination arm were diarrhea (13) and palmar plantar erythrodysesthesia (12). There was a 2 incidence of reversible decreased left ventricular function in the combination arm. The Oncologist 2008;13: INTRODUCTION Following therapy with an anthracycline, a taxane, and trastuzumab, treatment options for human epidermal growth factor receptor (HER)-2 overexpressing advanced or metastatic breast cancer are limited [1 3]. Lapatinib (Tykerb ; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1 (epidermal growth factor receptor) has demonstrated noncrossresistance with trastuzumab in both preclinical and clinical studies and is thus a possible therapeutic option [4, 5]. Moreover, in vitro data suggest that the combination of capecitabine and ErbB inhibitors can have synergistic activity in both high and low ErbB-expressing breast cancer cell lines [6, 7]. Capecitabine is already approved for the treatment of metastatic breast cancer resistant to both paclitaxel and anthracycline-containing chemotherapy regimens. To define the efficacy of lapatinib and support the proposed use of lapatinib plus capecitabine for the treatment of patients with HER-2 overexpressing metastatic breast cancer, a randomized, open-label study tested lapatinib in combination with capecitabine in the setting of ErbB-2 positive metastatic breast cancer that has been treated with an anthracycline, a taxane, and trastuzumab. A report of the study results was recently published [8]. PATIENTS AND METHODS The safety and efficacy of lapatinib in combination with capecitabine for the treatment of patients with HER-2 overexpressing metastatic breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were evaluated in a single multicenter, open-label, two-arm randomized trial conducted by GlaxoSmithKline. One hundred forty-one sites participated, with the majority of patients enrolled within the European Union (57) and U.S. (19). Eligibility criteria included histologically or cytologically proven breast cancer (stage IIIb or IV disease), documented ErbB-2 overexpression (immunohistochemistry [IHC] 3 or IHC 2 with fluorescence in situ hybridization [FISH] confirmation), prior therapy that included an anthracycline, a taxane (for adjuvant and/or metastatic disease), and trastuzumab (for advanced and/or metastatic disease), progression after hormone therapy for hormone receptor positive tumors, measurable lesion(s), age 18, an Eastern Cooperative Oncology Group performance status score of 0 or 1, normal cardiac ejection fraction, and adequate renal, hepatic, and bone marrow function. Women who were pregnant or lactating were excluded, as were women of childbearing potential unless adequate contraception was used. Patients were stratified at randomization by the site of metastasis (visceral versus nonvisceral) and stage of disease (stage IIIb versus IV) and received either lapatinib (1,250 mg once daily on days 1 21) plus capecitabine (1,000 mg/m 2 every 12 hours on days 1 14) every 21 days or capecitabine alone (1,250 mg/m 2 every 12 hours on days 1 14) every 21 days. The primary endpoint was time to progression (TTP), defined as time from randomization to tumor progression or death related to breast cancer. Progression was determined by a blinded independent review panel using the Response Evaluation Criteria in Solid Tumors. Tumor assessment was conducted every 6 weeks for the first 24 weeks, then every 12 weeks and at the end of treatment. Additional safety assessments were to be performed on all subjects every 3 weeks and at the end of treatment. Subjects withdrawn from the investigational drug who had not progressed were assessed every 12 weeks until progression. Thereafter, subjects were followed for survival at approximately 12-week intervals until death. The study was originally designed to have an 80 power to detect a 30 difference in overall survival with a planned sample size of 528 patients. RESULTS In total, 399 patients were randomized between March 29, 2004 and April 3, After the results of a prespecified interim analysis of 324 patients (cutoff date of November 15, 2005) were made available, further enrollment was discontinued after 399 patients were enrolled, 76 of the planned 528 patients. The final analysis includes 198 pa-
3 1116 Lapatinib and Capecitabine for HER-2 Overexpressing Metastatic Breast Cancer Table 1. Efficacy analyses: TTP November 15, 2005 cutoff n 324 April 3, 2006 cutoff n 399 a IND INV IND INV LC C LC C LC C LC C TTP n 163 n 161 n 163 n 161 n 198 n 201 n 198 n 201 Total events () 49 (30) 72 (45) 59 (36) 74 (46) 82 (41) 102 (51) 121 (61) 126 (63) Median TTP, weeks Improvement in median TTP, weeks HR (95 CI) 0.49 ( ) 0.59 ( ) 0.57 ( ) 0.72 ( ) p-value a Eighty-seven percent (347 of 399) of patients tumor assessment data were evaluable for the independent review committee. Abbreviations: C, capecitabine; CI, confidence interval; HR, hazard ratio; IND, independent reviewer analysis; INV, investigator s analysis; LC, lapatinib plus capecitabine; TTP, time to tumor progression. tients randomized to the lapatinib and capecitabine combination and 201 patients randomized to capecitabine alone (cutoff date of April ). The treatment groups were comparable for demographic characteristics at baseline: the median age was 53 years, with years old. Ninetyone percent were white. The two treatment groups were also comparable for tumor characteristics at inclusion. Ninety-seven percent of patients had stage IV disease, 77 had visceral stage IV and 20 had nonvisceral stage IV. Only 4 were stage IIIb or IIIc. Seventy-seven percent of patients were postmenopausal (lapatinib plus capecitabine, 81; capecitabine, 72). Forty-seven percent were estrogen receptor or progesterone receptor positive and 48 had received prior hormonal therapy. Ninety-five percent were ErbB-2 IHC 3 or IHC 2 with FISH confirmation. Approximately 95 of patients had prior treatment with a taxane, an anthracycline, and trastuzumab. Forty-six percent had received prior vinorelbine and 14 had received gemcitabine. Ninety-nine percent of patients had at least one measurable lesion. The mean duration of treatment was approximately 20 weeks for patients in the lapatinib plus capecitabine arm and approximately 15 weeks for patients receiving capecitabine alone. The daily dose of capecitabine was 20 higher in the control arm than in the lapatinib combination arm. As noted above, the study enrollment was discontinued early based on an independent data monitoring committee recommendation. Patient disposition and TTP results based on the two data cutoff dates are summarized in Table 1. TTP data were more mature at the clinical cutoff date of April 3, 2006, with 247 events identified by the investigators and 184 events identified by the independent review committee (planned final TTP analysis was at 266 events). TTP analyses by both the independent and investigator assessments at both cutoff dates were statistically significant. However, the longer median TTP was variable in the lapatinib and capecitabine combination arm and depended on whether the assessment was performed by the investigator or by the independent review panel, or whether the earlier or later data cutoff date was used. The median TTP of the control arm was consistent regardless of the cutoff and whether the assessment was by the independent review panel or the investigator. At the more mature April 3 update, an 8.5-week longer median TTP was observed in the lapatinib combination arm compared with the capecitabine alone arm. It is noteworthy that the number of TTP events identified by the independent assessment was substantially less than the number of events identified by investigators (Table 1). This was because the independent TTP assessment was based only on objective tumor assessments (not all assessments were available) and cancer deaths, whereas the investigator TTP assessment also included symptomatic progression. Additional reasons for differences between the independent review committee and investigator assessments also included the interpretation of data and/or different lesions/ organ selected. The objective response rate (complete responses plus partial responses) by independent review was 23.7 (95 confidence interval [CI], ) for the lapatinib combination arm and 13.9 (95 CI, ) for capecitabine alone. There was one complete response in the lapatinib combination arm and none in the capecitabine alone arm. The median response duration was 31.2 weeks in
4 Ryan, Ibrahim, Cohen et al Table 2. Adverse reactions occurring in 10 of patients Lapatinib (1,250 mg/day) capecitabine (2,000 mg/m 2 /day) Capecitabine (2,500 mg/m 2 /day) (n 198) (n 191) Adverse reactions Gastrointestinal disorders Diarrhea Nausea Vomiting Stomatitis Abdominal pain Dyspepsia Constipation Skin and s.c. tissue disorders Palmar plantar erythrodysesthesia Rash b Dry skin General disorders and administrative site conditions Fatigue Mucosal inflammation Asthenia Metabolism and nutrition disorders Anorexia Musculoskeletal and connective tissue disorders Pain in extremity Back pain Respiratory, thoracic, and mediastinal disorders Dyspnea Nervous system disorder Headache Psychiatric disorders Insomnia a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. b 3 dermatitis acneiform was reported in 1 of patients in the lapatinib plus capecitabine group. the lapatinib plus capecitabine arm and 30.6 weeks in the capecitabine alone arm. At the April 3, 2006 cutoff date, only 30 of the patients had died (55 patients, 28, in the lapatinib plus capecitabine group and 64 patients, 32, in the capecitabine group). Survival data are not mature enough to conduct a formal comparative analysis at this time. Clinical treatment emergent adverse reactions (regardless of relationship to study drug) are summarized in Table 2 and laboratory adverse reactions are summarized in Table 3. Although the toxicities observed in the lapatinib combination arm were similar to those in the capecitabine alone arm, a higher incidence of diarrhea and rash was noted with the combination therapy. The most common adverse reactions ( 15) during therapy with lapatinib plus capecitabine were gastrointestinal (diarrhea, 65; nausea, 44; vomiting, 26) or dermatologic, such as palmar plantar erythrodysesthesia (PPE, 53) and rash (28). Fatigue was noted in 23 of patients and stomatitis occurred in 14 of patients. The most common grade 3 or 4 adverse reactions for the lapatinib and capecitabine combination were diarrhea (14) and PPE (12). Fourteen percent of
5 1118 Lapatinib and Capecitabine for HER-2 Overexpressing Metastatic Breast Cancer Table 3. Laboratory adverse reactions Adverse reactions Lapatinib capecitabine patients discontinued therapy because of any adverse event and 5 discontinued because of diarrhea. The important laboratory adverse reactions were anemia (56), neutropenia (22), thrombocytopenia (18), and abnormalities of transaminases (aspartate aminotransferase, 49; alanine aminotransferase, 37) and bilirubin (45), similar to those observed in the control arm. A 2 incidence of generally reversible decreased left ventricular function in the combination arm was noted. Although QT prolongation has been observed with lapatinib use, torsade de pointes has not been reported. DISCUSSION This phase III, randomized trial comparing lapatinib in combination with capecitabine with capecitabine alone provides support for the use of the lapatinib combination in the treatment of HER-2 overexpressing metastatic breast cancer by demonstrating a TTP advantage supported by an objective response rate improvement. TTP, the primary efficacy endpoint, included both disease progression and death resulting from breast cancer as assessed by an independent review committee. Advantages of TTP as an endpoint include earlier reporting of results, no confounding effect of treatment subsequent to progression, and a smaller sample size required to show a longer TTP than to show longer survival. However, TTP is a softer endpoint that depends on the time of tumor evaluation and does not necessarily represent the natural time when progression occurs. Irregularities in the frequency or interval of clinical and radiological assessments to document progression and missing data can introduce bias. Another disadvantage in using TTP is that a large number of scans can markedly increase the cost of the study. In this study, TTP was evaluated by a blinded independent review committee. The advantage of blinded review is Capecitabine Hematologic Hemoglobin Platelets Neutrophils Hepatic Total bilirubin Aspartate aminotransferase Alanine aminotransferase a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. that it can potentially decrease bias in an open-label study design. However, it is dependent on investigator data collection. Thus, when an investigator believes that a patient s disease has progressed, further diagnostic evaluation may not be performed. In this situation, if the independent reviewer does not concur with the investigator s assessment of progression, then the independent reviewer can choose to censor the patient (no event) on the date of the last complete diagnostic evaluation, because further tumor assessments may not be available. This may lead to an overestimation of the treatment effect for both arms, assuming the errors are evenly distributed. If there is a large amount of missing or censored data, especially compared with the investigator reported assessment, then this may lead to an erroneous result. In this study, although the protocol-specified duration between two tumor assessments was at most 6 weeks, the time from the last tumor evaluation to the data cutoff date was 100 days in 31 of evaluable patients (see Table 1 footnote) in the independent assessment compared with 13 of patients in the investigator assessment. This suggests that either the independent reviewer did not concur with the investigator assessment or that not all scans were available to the independent reviewer at the time of the data cutoff date. Early termination of a study can introduce some major problems. A smaller sample size and crossover of patients from the capecitabine alone arm to the lapatinib combination arm may reduce the chance of detecting a survival difference. However, a follow-up survival analysis is planned when 75 of events have occurred and is projected to be completed in Because of the early termination and differences in the investigator and independent assessments of progression, an accurate determination of the magnitude of the TTP difference cannot be made. Although statistically significant differences between the treatment arms were observed consistently, the initially longer TTP was
6 Ryan, Ibrahim, Cohen et al lower when analyzed approximately 4 months later (the difference in the median TTP decreased from 17.6 weeks to 8.5 weeks, Table 1). Based on the result of this study, regular approval was granted on March 13, The approved indication is for lapatinib to be used in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER-2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. ACKNOWLEDGMENTS The views expressed are the result of independent work and do not necessarily represent the views and findings of the U.S. Food and Drug Administration. AUTHOR CONTRIBUTIONS Conception/design: Qin Ryan, Amna Ibrahim, Martin H. Cohen, John Johnson, Chia-wen Ko, Rajeshwari Sridhara Data analysis and interpretation: Qin Ryan, Amna Ibrahim, Chia-wen Ko, Rajeshwari Sridhara Manuscript writing: Qin Ryan, Amna Ibrahim, Martin H. Cohen, John Johnson, Chia-wen Ko, Rajeshwari Sridhara, Robert Justice Final approval of manuscript: Robert Justice, Richard Pazdur REFERENCES 1 Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23: Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumabbased therapy. The Oncologist 2006;11: Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66: Spector NL, Xia W, Burris H 3rd et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23: Mandelblat J, Bashir T, Budman DR. Capecitabine-docetaxel combination treatment. Expert Rev Anticancer Ther 2006;6: Budman DR. New directions with capecitabine combinations in advanced breast cancer. Oncology (Williston Park) 2002;16(suppl 12): Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:
Immunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWARNING LETTER. According to the INDICATIONS AND USAGE section of the FDA-approved product labeling (PI)' for Tykerb:
EPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Chief Executive Officer GlaxoSmithKline P.O. Box 13398 Five Moore
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationBreast Cancer. Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer Outcome of Patients with HER2-Positive Advanced
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationKey Words. Imatinib Gleevec KIT CD117 Gastrointestinal stromal tumors
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationKey Words. Bevacizumab Avastin Nonsquamous Non-small cell lung cancer First-line Advanced/metastatic disease
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Bevacizumab (Avastin ) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell
More informationTaxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1
Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast
More informationEmerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ
Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms
More informationLapatinib plus Letrozole as First-Line Therapy for HER-2 Hormone Receptor Positive Metastatic Breast Cancer
The Oncologist Academia Pharma Intersect: Breast Cancer Lapatinib plus Letrozole as First-Line Therapy for HER-2 Hormone Receptor Positive Metastatic Breast Cancer LEE S. SCHWARTZBERG, a SANDRA X. FRANCO,
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PERJETA safely and effectively. See full prescribing information for PERJETA. PERJETA (pertuzumab)
More informationBRAVTRAD. Protocol Code: Breast. Tumour Group: Dr. Susan Ellard. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN) and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour Group: Contact
More informationKey Words. Erlotinib Non-small cell lung cancer Maintenance treatment
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationStudy Period: 27 March 2008 (first subject enrolled) to 05 May 2010 (data cutoff date for primary analysis)
Date: 20 July 2011 Page 2 of 3375 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C US Name of Finished Product: Not applicable Name of ctive Ingredient: Ganitumab (MG 479) Title of Study: n International,
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Trastuzumab Emtansine (Kadcyla) for Metastatic Breast Cancer January 10, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Trastuzumab Emtansine (Kadcyla) for Metastatic Breast Cancer January 10, 2014 DISCLAIMER Not a Substitute for Professional Advice This report
More informationMEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc
MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationIn first-line HER2+ METASTATIC breast cancer TREAT HER 2 PROGRESSION OR UNACCEPTABLE TOXICITY
In first-line HER2+ METASTATIC breast cancer TREAT HER 2 PROGRESSION OR UNACCEPTABLE TOXICITY The most common adverse reactions (>30) with PERJETA in combination with trastuzumab and docetaxel were diarrhea,
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationPhase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint
For immediate release: April 15, 2015 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Announces PALOMA-3 Trial for IBRANCE (Palbociclib) Stopped Early Due
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationCorporate Medical Policy
Corporate Medical Policy Pertuzumab for Treatment of Malignancies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pertuzumab_for_treatment_of_malignancies 2/2013 4/2017 4/2018 6/2017
More informationLapatinib and capecitabine for breast cancer Funding arrangements to be set up and specified locally Page 1 of 5
Indication: Funding arrangements to be set up and specified locally Page 1 of 5 Lapatinib in combination with Capecitabine is recommended as a treatment option for people with advanced and/or metastatic
More informationINNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB
INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB Elena Massa CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA DEGLI STUDI DI CAGLIARI ErbB Inhibition
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationKeywords Breast cancer Brain metastasis Lapatinib Capecitabine. Introduction
Int Canc Conf J (2013) 2:9 13 DOI 10.1007/s13691-012-0054-x CASE REPORT HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura
More informationOnline-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
More informationLow Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline
Low Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline Rabab Mahmoud and Omnia Abd-elfattah Clinical Oncology Department,
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationIn HER2+ breast cancer: 2 INDICATIONS. PERJETA + Herceptin-based therapy dosing durations 1 CONTINUE UNTIL PROGRESSION OR UNACCEPTABLE TOXICITY
Recommended dosing for PERJETA + Herceptin-based treatment in HER2+ METASTATIC breast cancer TREAT HER 2 PROGRESSION OR UNACCEPTABLE TOXICITY METASTATIC: Administer every 3 weeks until disease progression
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationOffice of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Panitumumab (Vectibix ) RUTHANN M. GIUSTI, KAUSHIKKUMAR A. SHASTRI, MARTIN H. COHEN, PATRICIA KEEGAN, RICHARD PAZDUR Office of Oncology
More informationTykerb. Tykerb (lapatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tykerb Page: 1 of 5 Last Review Date: June 24, 2016 Tykerb Description Tykerb (lapatinib) Background
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationReDOS Trial Background
Regorafenib Dose Optimization Study (ReDos) A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mcrc) Abstract
More informationTykerb. Tykerb (lapatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.23 Subject: Tykerb Page: 1 of 5 Last Review Date: December 8, 2017 Tykerb Description Tykerb (lapatinib)
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationAUSTRALIAN PRODUCT INFORMATION - TYKERB (lapatinib) 250 mg tablets
AUSTRALIAN PRODUCT INFORMATION - TYKERB (lapatinib) 250 mg tablets 1. NAME OF THE MEDICINE Lapatinib (as ditosilate monohydrate) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance Each TYKERB
More informationA BS TR AC T. n engl j med 367;19 nejm.org november 8,
The new england journal of medicine established in 1812 november 8, 2012 vol. 367 no. 19 Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Sunil Verma, M.D., David Miles, M.D., Luca Gianni,
More informationMEET MARY KISQALI PATIENT PROFILES
KISQALI PATIENT PROFILES MEET MARY Mary was recently diagnosed with HR+/HER2- metastatic breast cancer Review the data from the MONALEESA-2 trial to see how patients like Mary responded The patient profile
More informationReceiving PERJETA + Herceptinbased therapy * after surgery
Treatment after surgery for HER2+ early breast cancer that has a high risk of coming back Receiving PERJETA + Herceptinbased therapy * after surgery PERJETA is part of an FDA-approved treatment regimen
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationFor more information, call AstraZeneca Access 360 at ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET.
1-844-ASK-A360 1-844-275-2360 1-844-FAX-A360 1-844-329-2360 www.myaccess360.com For more information, call AstraZeneca Access 360 at 1-844-ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET. Indications
More informationTYKERB PRODUCT INFORMATION (Lapatinib Ditosylate) 250 mg tablets
TYKERB PRODUCT INFORMATION (Lapatinib Ditosylate) 250 mg tablets NAME OF THE DRUG TYKERB film-coated tablets contain lapatinib ditosylate which is a member of 4- anilinoquinazoline class of kinase inhibitors.
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Eribulin (Halaven) for Metastatic Breast Cancer August 2, 2012
pan-canadian Oncology Drug Review Final Clinical Guidance Report Eribulin (Halaven) for Metastatic Breast Cancer August 2, 2012 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 29 th Prioritization 4 th quarter 2016 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Claudia Wild Please note: Within
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationSupplementary Online Content
Supplementary Online Content Chawla SP, Papai Z, Mukhametshina G, et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationBenefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
Regulatory Issues: FDA Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib LORRAINE PELOSOF, STEVEN LEMERY, SANDRA
More informationName of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.
More informationNPAC+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationDrafting a Coverage Authorization Request Letter
Drafting a Coverage Authorization Request Letter The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations,
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationThe issues that will be resolved through PMCs include the the requalification of bioburden test.
BLA 125409/0_ Perjeta (pertuzumab) 4 patients with normal renal function. No dose adjustment can be recommended for patients with severe renal impairment because of the limited pharmacokinetic data available.
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More information